Ken Griffin Gamida Cell Ltd. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.04 - $0.46 $755 - $8,689	18,890 New	18,890 $0
Q4 2022 Feb 14, 2023	BUY	$1.15 - $2.1 $5,534 - $10,107	4,813 Added 18.99%	30,163 $38,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $38,785 - $85,936	25,350 New	25,350 $40,000
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $58,847 - $118,490	-26,508 Reduced 44.86%	32,577 $135,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $28,622 - $58,024	13,010 Added 28.24%	59,085 $150,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $24,828 - $41,531	6,449 Added 16.27%	46,075 $181,000
Q2 2021 Aug 16, 2021	SELL	$5.85 - $8.33 $43,524 - $61,975	-7,440 Reduced 15.81%	39,626 $254,000
Q1 2021 May 17, 2021	BUY	$7.8 - $12.43 $233,422 - $371,980	29,926 Added 174.6%	47,066 $381,000
Q4 2020 Feb 16, 2021	BUY	$4.07 - $11.0 $6,654 - $17,985	1,635 Added 10.54%	17,140 $144,000
Q3 2020 Nov 16, 2020	BUY	$3.93 - $4.59 $60,934 - $71,167	15,505 New	15,505 $64,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.